

DAFTAR PUSTAKA

- Afrine, S., Haque, J. A., Morshed, M. S., Banu, H., Hossain, A., & Hasanat, M. A. (2023). Ovarian volume is more closely related to the different manifestations of polycystic ovary syndrome than follicle number per ovary. *Clinical and experimental reproductive medicine*, 50(3), 200–205. Available at: <https://doi.org/10.5653/term.2023.05897>.
- Azziz, R., Enrico, C., Didier, D., Evanthia, DK., Hector, F. EM., Walter, F., Onno, E. J., Richard, S. L., Robert, J. N., Ann, E. T., & Selma, F. W. 2006. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline. *The Journal of Clinical Endocrinology & Metabolism*, 91(11), 4237–4245. Available at: <https://doi.org/10.1210/jc.2006-0178>.
- Chang, R., Kazer, R. (2014). Polycystic Ovary Syndrome. *Glob. libr. women's med.*, (ISSN: 1756-2228) 2014; DOI 10.3843/GLOWM.10301
- Chun S. (2014). Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome. *Clinical and experimental reproductive medicine*, 41(2), 86–91. Available at: <https://doi.org/10.5653/term.2014.41.2.86>.
- Damayanti, D., Ega, A. T., Ema, Y., Belet, L. I., & Tirolyn, P. 2022. Hubungan Tingkat Stres dengan Siklus Menstruasi Mahasiswi Fakultas Keperawatan di Universitas Swasta di Tangerang. *Jurnal Kedokteran dan Kesehatan*, 18(2), 212-219.
- Dhonnabhain, B. N. 2023. Luteinizing Hormone. University College London.
- Elasam, A.N., Ahmed, M.A., Ahmed, A.B.A. *et al.* (2022). The prevalence and phenotypic manifestations of polycystic ovary syndrome (PCOS) among infertile Sudanese women: a cross-sectional study. *BMC Women's Health* 22, 165. Available at: <https://doi.org/10.1186/s12905-022-01762-6>.
- Escobar-Morreale H. F. (2018). Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. *Nature reviews. Endocrinology*, 14(5), 270–284. Available at: <https://doi.org/10.1038/nrendo.2018.24>.
- Freeman, A.M., Acevedo, L.A. and Pennings, N. (2023) *Insulin Resistance*.
- Fulghesu, A. M., Angioni, S., Frau, E., Belosi, C., Apa, R., Mioni, R., Xamin, N., Capobianco, G. P., Dessole, S., Fruzzetti, F., Lazzarini, V., Minerba, L., Melis, G. B., & Lanzone, A. (2007). Ultrasound in polycystic ovary syndrome--the measuring of ovarian stroma and relationship with

circulating androgens: results of a multicentric study. *Human reproduction (Oxford, England)*, 22(9), 2501–2508. Available at: <https://doi.org/10.1093/humrep/dem202>.

Gibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2017). Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome. *The Journal of clinical endocrinology and metabolism*, 102(2), 604–612. Available at: <https://doi.org/10.1210/jc.2016-2963>.

Głuszak, O., Stopińska-Głuszak, U., Glinicki, P., Kapuścińska, R., Snochowska, H., Zgliczyński, W., & Dębski, R. (2012). Phenotype and metabolic disorders in polycystic ovary syndrome. *ISRN endocrinology*, 2012, 569862. Available at: <https://doi.org/10.5402/2012/569862>.

Han, Y. S., Lee, A. R., Song, H. K., Choi, J. I., Kim, J. H., Kim, M. R., & Kim, M. J. (2017). Ovarian Volume in Korean Women with Polycystic Ovary Syndrome and Its Related Factors. *Journal of menopausal medicine*, 23(1), 25–31. Available at: <https://doi.org/10.6118/jmm.2017.23.1.25>.

Harada, M. (2022). Pathophysiology of polycystic ovary syndrome revisited: Current understanding and perspectives regarding future research. *Reproductive Medicine and Biology*, 22(1), 1-13. Available at: <https://doi.org/10.1002/rmb2.12487>.

Hariri L, Rehman A. Estradiol. [Updated 2023 Jun 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi-nlm-nih-gov.translate.goog/books/NBK549797/?_x_tr_sl=en&_x_tr_tl=id&_x_tr_hl=id&_x_tr_pto=sc.

Hong SH, Sung YA, Hong YS, Jeong K, Chung H, Lee H. 2017. Polycystic ovary morphology is associated with insulin resistance in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)*, 87: 375–80.

Jonard, S., Robert, Y., Cortet-Rudelli, C., Pigny, P., Decanter, C., & Dewailly, D. (2003). Ultrasound examination of polycystic ovaries: is it worth counting the follicles?. *Human reproduction (Oxford, England)*, 18(3), 598–603. Available at: <https://doi.org/10.1093/humrep/deg115>.

Khan, M. J., Ullah, A., & Basit, S. (2019). Genetic Basis of Polycystic Ovary Syndrome (PCOS): Current Perspectives. *The application of clinical genetics*, 12, 249–260. Available at: <https://doi.org/10.2147/TACG.S200341>.

Le, N. S. V., Minh, T. L., Nguyen, D. N., Nhu, Q. T. T., Quoc, H. V. N., & Thanh, N.C. 2021. A Cross-Sectional Study on Potential Ovarian Volume and

Related Factors in Women with Polycystic Ovary Syndrome from Infertile Couples. *International Journal of Women's Health*, 13, 793–801. Available at: <https://doi.org/10.2147/IJWH.S329082>.

Lee, J. E., Park, Y., Lee, J., & Chun, S. (2023). Association between polycystic ovarian morphology and insulin resistance in women with polycystic ovary syndrome. *Clinical and experimental reproductive medicine*, 50(2), 117–122. Available at: <https://doi.org/10.5653/cerm.2023.05855>.

Lewandowski, K. C., Skowrońska-Jóźwiak, E., Łukasiak, K., Gałuszko, K., Dukowicz, A., Cedro, M., & Lewiński, A. (2019). How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models. *Archives of medical science : AMS*, 15(3), 613–618. Available at: <https://doi.org/10.5114/aoms.2019.82672>.

Mansour, A., Hashemi Taheri, A.P., Moradi, B. *et al.* (2022). Ovarian volume, not follicle count, is independently associated with androgens in patients with polycystic ovary syndrome. *BMC Endocr Disord* 22, 298. Available at: <https://doi.org/10.1186/s12902-022-01224-y>.

Masoodian, S. M., Omidifar, A., Moradkhani, S., Asiabanha, M., & Khoshmirsafa, M. (2022). HOMA-IR mean values in healthy individuals: a population-based study in iranian subjects. *Journal of diabetes and metabolic disorders*, 22(1), 219–224. Available at: <https://doi.org/10.1007/s40200-022-01099-9>.

Mathew TK, Zubair M, Tadi P. Blood Glucose Monitoring. [Updated 2023 Apr 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi-nlm-nih-gov.translate.goog/books/NBK555976/?_x_tr_sl=en&_x_tr_tl=id&_x_tr_hl=id&_x_tr_pto=sc.

Matsuba, I., Saito, K., Takai, M., Hirao, K., Sone, H., & Japan Diabetes Clinical Data Management Study Group (2012). Fasting insulin levels and metabolic risk factors in type 2 diabetic patients at the first visit in Japan: a 10-year, nationwide, observational study (JDDM 28). *Diabetes care*, 35(9), 1853–1857. Available at: <https://doi.org/10.2337/dc12-0156>.

Matsuzaki, T., Munkhzaya, M., Iwasa, T., Tungalagsuvd, A., Yano, K., Mayila, Y., Yanagihara, R., Tokui, T., Kato, T., Kuwahara, A., Matsui, S., & Irahara, M. (2017). Relationship between serum anti-Müllerian hormone and clinical parameters in polycystic ovary syndrome. *Endocrine journal*, 64(5), 531–541. Available at: <https://doi.org/10.1507/endocrj.EJ16-0501>.

Moolhuijsen, L. M. E., Jenny A. V., 2020. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function, *The Journal of Clinical*

Endocrinology & Metabolism, Volume 105, Issue 11, Pages 3361–3373,
Available at: <https://doi.org/10.1210/clinem/dgaa513>.

Nedresky D, Singh G. Physiology, Luteinizing Hormone. [Updated 2022 Sep 26].
In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023
Jan-. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK539692/>.

Oh, S. R., Choe, S. Y., & Cho, Y. J. (2019). Clinical application of serum anti-Müllerian hormone in women. *Clinical and experimental reproductive medicine*, 46(2), 50–59. Available at:
<https://doi.org/10.5653/cerm.2019.46.2.50>.

Orlowski M, Sarao MS. Physiology, Follicle Stimulating Hormone. [Updated 2023 May 1]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available at:
<https://www.ncbi.nlm.nih.gov/books/NBK535442/>.

Patel N, Zafar Gondal A. Embryology, Mullerian-inhibiting Factor. [Updated 2023 Aug 14]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available at:
<https://www.ncbi.nlm.nih.gov/books/NBK544351/>.

Rasquin LI, Anastasopoulou C, Mayrin JV. Polycystic Ovarian Disease. 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK459251/>.

Richard A. Kronmal, Joshua I. Barzilay, Russell P. Tracy, Peter J. Savage, Trevor J. Orchard, Gregory L. Burke. 2004. The Relationship of Fasting Serum Radioimmune Insulin Levels to Incident Coronary Heart Disease in an Insulin-Treated Diabetic Cohort, *The Journal of Clinical Endocrinology & Metabolism*, Volume 89, Issue 6, Pages 2852–2858, <https://doi.org/10.1210/jc.2003-031822>.

Rodigro, A., Joel, G.B., Marta, B.G., Sara, S., & Romina, P., 2020. Table of female hormone values.

Saadia Z. (2020). Follicle Stimulating Hormone (LH: FSH) Ratio in Polycystic Ovary Syndrome (PCOS) - Obese vs. Non- Obese Women. *Medical archives (Sarajevo, Bosnia and Herzegovina)*, 74(4), 289–293. Available at: <https://doi.org/10.5455/medarh.2020.74.289-293>.

Saftarina, F & Indriani, N. W. P., 2016. Pengaruh Sindrom Polikistik Ovarium terhadap Peningkatan Faktor Risiko Infertilitas. *Majority*, 5(2), 43-48.

Sheng, C., Zhang, J., & Jue, J. (2022). The Relationship between Ovarian Ultrasound Parameters and Endocrine and Metabolic Indicators in Patients with Ovarian Syndrome. *Evidence-based complementary and alternative*

medicine : *eCAM*, 2022, 7238344. Available at:
<https://doi.org/10.1155/2022/7238344>.

Shirazi, F. K. H., Khodamoradi, Z., & Jeddi, M. (2021). Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with Polycystic Ovarian Syndrome (PCOS). *BMC Endocrine Disorders*, 21(1). Available at: <https://doi.org/10.1186/s12902-021-00710-z>.

Singh, S., Pal, N., Shubham, S., Sarma, D. K., Verma, V., Marotta, F., & Kumar, M. (2023). Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics. *Journal of clinical medicine*, 12(4), 1454. Available at: <https://doi.org/10.3390/jcm12041454>.

Sirmans, S. M., & Pate, K. A. (2013). Epidemiology, diagnosis, and management of polycystic ovary syndrome. *Clinical epidemiology*, 6, 1–13. Available at: <https://doi.org/10.2147/CLEP.S37559>.

Teede, H., Marie, M., Michael, C., Anuja, D., Joop, L., Lisa, M., Terhi, P. & Robert, N. 2018. *International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2018*. Melbourne: Monash University.

Thomas, D. D., Corkey, B. E., Istfan, N. W., & Apovian, C. M. (2019). Hyperinsulinemia: An Early Indicator of Metabolic Dysfunction. *Journal of the Endocrine Society*, 3(9), 1727–1747. <https://doi.org/10.1210/js.2019-00065>

Wahyuni, M., Eva, D., & Putri, S. L. (2015). Hubungan Resistensi Insulin dengan Gambaran Klinis Sindrom Ovarium Polikistik. *Jurnal Kesehatan Andalas*, 4(3), 908-916.

Wilcox G. (2005). Insulin and insulin resistance. *The Clinical biochemist. Reviews*, 26(2), 19–39.

Yau, T. T., Ng, N. Y., Cheung, L. P., & Ma, R. C. (2017). Polycystic ovary syndrome: a common reproductive syndrome with long-term metabolic consequences. *Hong Kong medical journal = Xianggang yi xue za zhi*, 23(6), 622–634. Available at: <https://doi.org/10.12809/hkmj176308>.